Emergent BioSolutions (NYSE: EBS) reported Q1 EPS of $1.53, $0.41 better than the analyst estimate of $1.12. Revenue for the quarter came in at $343 million versus the consensus estimate of $358.47 million.

GUIDANCE:

Emergent BioSolutions sees Q2 2021 revenue of $370-430 million, versus the consensus of $502.3 million.

For earnings history and earnings-related data on Emergent BioSolutions (EBS) click here.